Bank Of New York Mellon Corp Athira Pharma, Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$2.26 - $4.22 $249,424 - $465,740	110,365 New	110,365 $276 Million
Q4 2022 Feb 14, 2023	BUY	$2.76 - $3.71 $309,313 - $415,779	112,070 New	112,070 $355,000
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $45,403 - $61,364	15,496 Added 16.43%	109,796 $326,000
Q2 2022 Aug 15, 2022	SELL	$2.74 - $13.43 $28,819 - $141,256	-10,518 Reduced 10.03%	94,300 $287,000
Q1 2022 May 11, 2022	BUY	$8.96 - $13.51 $8,601 - $12,969	960 Added 0.92%	104,818 $1.42 Million
Q4 2021 Feb 11, 2022	BUY	$9.17 - $16.39 $59,210 - $105,830	6,457 Added 6.63%	103,858 $1.35 Million
Q3 2021 Nov 12, 2021	BUY	$9.15 - $11.09 $129,298 - $156,712	14,131 Added 16.97%	97,401 $914,000
Q2 2021 Aug 11, 2021	BUY	$10.24 - $20.87 $487,342 - $993,245	47,592 Added 133.39%	83,270 $852,000
Q1 2021 May 13, 2021	SELL	$16.9 - $29.77 $72,551 - $127,802	-4,293 Reduced 10.74%	35,678 $656,000
Q4 2020 Feb 09, 2021	BUY	$16.48 - $34.3 $658,722 - $1.37 Million	39,971 New	39,971 $1.37 Million

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $21.9M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.